author-photo

Bushi Wang

Boehringer Ingelheim

38

Papers

2086

Citations

Citation Trend

Filter By

Papers (24) Sort By

Journal Conference Others

Rejoinder for discussions on correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials

2021 Biometrical Journal
Show All
- Source
- Cite
- Save
Citations (0)
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

2019 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design

2018
Show All
- Source
- Cite
- Save
Citations (4)
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

2018 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (18)
An improved uniformly more powerful exact Fisher–Hayter pairwise comparisons procedure

2017 Biometrical Journal
- Bushi Wang
- Xinping Cui
Show All
- Source
- Cite
- Save
Citations (3)
Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (17)
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

2017 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (11)
Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Rationale and Design of a Phase III Single-Arm Multicenter Study of Dabigatran Etexilate for the Secondary Prevention of Venous Thromboembolism in Children

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)